Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Piotroski F-Score: 7 (As of Jun. 30, 2026) — 17% Above Median


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
86 GF Score
Price ¥52.04
GF Value ¥60.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 -1.68% 86 Piotroski F-Score is 7 as of Jun. 30, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates SHSE:600276 with a GF Score™ of 86/100 and a GF Value™ of ¥60.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 978 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 91.82% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Hengrui Pharmaceuticals Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score or its related term are showing as below:

SHSE:600276' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Jiangsu Hengrui Pharmaceuticals Co was 9. The lowest was 2. And the median was 6.

Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Related Terms


Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 8.00 7.00 5.00

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 5.00 7.00

SHSE:600276 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score falls into.


SHSE:600276
86GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 2576.051 + 1301.063 + 1959.885 + 2282.268 = ¥8,119 Mil.
Cash Flow from Operations was 3745.279 + 4809.977 + 2124.948 + 786.446 = ¥11,467 Mil.
Revenue was 8555.583 + 7426.888 + 8441.334 + 8140.565 = ¥32,564 Mil.
Gross Profit was 7509.283 + 6346.409 + 7274.12 + 7049.616 = ¥28,179 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(51292.782 + 62893.517 + 68327.54 + 69867.316 + 71293.862) / 5 = ¥64735.0034 Mil.
Total Assets at the begining of this year (Mar25) was ¥51,293 Mil.
Long-Term Debt & Capital Lease Obligation was ¥37 Mil.
Total Current Assets was ¥52,044 Mil.
Total Current Liabilities was ¥5,637 Mil.
Net Income was 2062.819 + 1187.828 + 1716.951 + 1874.056 = ¥6,842 Mil.

Revenue was 7603.2 + 6588.57 + 7795.301 + 7205.611 = ¥29,193 Mil.
Gross Profit was 6672.746 + 5628.691 + 6780.307 + 6136.949 = ¥25,219 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(46340.001 + 48181.36 + 48338.099 + 50135.645 + 51292.782) / 5 = ¥48857.5774 Mil.
Total Assets at the begining of last year (Mar24) was ¥46,340 Mil.
Long-Term Debt & Capital Lease Obligation was ¥63 Mil.
Total Current Assets was ¥35,970 Mil.
Total Current Liabilities was ¥3,363 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Hengrui Pharmaceuticals Co's current Net Income (TTM) was 8,119. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Hengrui Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 11,467. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=8119.267/51292.782
=0.15829258

ROA (Last Year)=Net Income/Total Assets (Mar24)
=6841.654/46340.001
=0.14764035

Jiangsu Hengrui Pharmaceuticals Co's return on assets of this year was 0.15829258. Jiangsu Hengrui Pharmaceuticals Co's return on assets of last year was 0.14764035. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jiangsu Hengrui Pharmaceuticals Co's current Net Income (TTM) was 8,119. Jiangsu Hengrui Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 11,467. ==> 11,467 > 8,119 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=37.103/64735.0034
=0.00057315

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=62.712/48857.5774
=0.00128357

Jiangsu Hengrui Pharmaceuticals Co's gearing of this year was 0.00057315. Jiangsu Hengrui Pharmaceuticals Co's gearing of last year was 0.00128357. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=52044.195/5636.724
=9.23305718

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=35969.766/3362.881
=10.69611622

Jiangsu Hengrui Pharmaceuticals Co's current ratio of this year was 9.23305718. Jiangsu Hengrui Pharmaceuticals Co's current ratio of last year was 10.69611622. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jiangsu Hengrui Pharmaceuticals Co's number of shares in issue this year was 6712.554. Jiangsu Hengrui Pharmaceuticals Co's number of shares in issue last year was 6246.852. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=28179.428/32564.37
=0.86534541

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=25218.693/29192.682
=0.86387037

Jiangsu Hengrui Pharmaceuticals Co's gross margin of this year was 0.86534541. Jiangsu Hengrui Pharmaceuticals Co's gross margin of last year was 0.86387037. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=32564.37/51292.782
=0.63487237

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=29192.682/46340.001
=0.62996723

Jiangsu Hengrui Pharmaceuticals Co's asset turnover of this year was 0.63487237. Jiangsu Hengrui Pharmaceuticals Co's asset turnover of last year was 0.62996723. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Hengrui Pharmaceuticals Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Piotroski F-Score of 7 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #80 out of 978 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score too high?
Jiangsu Hengrui Pharmaceuticals Co's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Jiangsu Hengrui Pharmaceuticals Co's value of 7 is 40% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #80 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #80 out of 978 companies for Piotroski F-Score. This places Jiangsu Hengrui Pharmaceuticals Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Jiangsu Hengrui Pharmaceuticals Co's value of 7 is 40% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥52.04 — trading 13.8% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Drug Manufacturers industry median of 5.00. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Piotroski F-Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥52.04 is trading 13.8% below its estimated GF Value™ of ¥60.34. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: ¥60.34 vs. price of ¥52.04 (13.8% below fair value)
  • GF Score™: 86/100 with 1 warning sign
  • Industry Position: 40% above the Drug Manufacturers median (#80 of 978)

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score

Get the complete analysis for SHSE:600276

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥52.04
Price
¥60.34
GF Value